Mirum Pharmaceuticals (MIRM) Cash & Current Investments (2018 - 2026)

Mirum Pharmaceuticals' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $386.3 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 39.11% year-over-year to $386.3 million in Q1 2026; TTM through Mar 2026 was $386.3 million, a 39.11% increase from a year earlier, with the FY2025 full-year figure at $383.3 million, up 36.54% from the prior year.
• Cash & Current Investments grew to $386.3 million in Q1 2026 per MIRM's latest filing, from $383.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $434.9 million in Q3 2022 and bottomed at $94.0 million in Q3 2025.
• The 5-year median for Cash & Current Investments is $286.3 million (2023), against an average of $280.5 million.
• Across the five-year window, Cash & Current Investments jumped 129.3% in 2024 and sank 66.95% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $251.7 million in 2022, then advanced by 13.75% to $286.3 million in 2023, then slipped by 1.95% to $280.7 million in 2024, then jumped by 36.54% to $383.3 million in 2025, then climbed by 0.76% to $386.3 million in 2026.
• Per Business Quant, the three latest MIRM Cash & Current Investments figures stand at $386.3 million (Q1 2026), $383.3 million (Q4 2025), and $94.0 million (Q3 2025).